SamaCare

Overview

SamaCare is a medical-benefit prior authorization platform for provider-administered specialty therapies. It is most relevant to pharma access teams when a therapy is bought and billed through specialty practices, infusion centers, retina groups, oncology clinics, neurology practices, or rheumatology practices rather than routed primarily through pharmacy-benefit ePA.

The platform’s public buyer fit is two-sided. Specialty practices use SamaCare to submit and manage prior authorizations. Manufacturers use the resulting workflow data and intervention infrastructure to understand where patients are delayed, denied, abandoned, or missing required documentation in the script-to-therapy journey.

Reimbursement and PA Capability Model

The framework below standardizes how Rx Almanac evaluates reimbursement-prior-auth capabilities, so buyers can compare vendors like-for-like while the readout column stays vendor-specific. For this table, SamaCare is evaluated as medical-benefit prior authorization platform for provider-administered specialty therapies.

Capability	Buyer should compare	SamaCare readout
Electronic PA initiation and payer connectivity	ePA submission, payer integrations, plan-specific requirements, real-time decisioning, and transaction reach.	Core. SamaCare is clearest where medical-benefit PA complexity is the access bottleneck.
Benefits verification and coverage discovery	Eligibility, pharmacy/medical benefit checks, policy criteria, coverage route, and reimbursement path identification.	Intake workflow. Public sources describe enrollment and benefits workflow adjacency; buyers should validate hub-specific integration scope.
Clinical documentation and appeals support	Document collection, criteria matching, appeal packets, peer-to-peer prep, and denial management.	Not the main buying reason for SamaCare; validate only if the SOW includes clinical documentation and appeals support.
Provider workflow integration	EHR, portal, fax, call, pharmacy, and practice-management workflows that reduce office burden.	Core. The platform is practice-facing, so manufacturer value depends on provider adoption and workflow trust. Confirm field execution. SamaCare can complement hub workflows, but buyer diligence should define who owns case status, outreach, and escalation.
Automation, AI, and queue prioritization	AI agents, rules engines, form completion, status retrieval, queue triage, and exception handling.	Automation workflow. SamaCare Plus and related company materials emphasize AI-guided prior authorization with provider control.
Reporting, status visibility, and policy intelligence	Case status, payer trend reporting, denial reasons, turnaround metrics, and policy-change intelligence.	Core. SamaCare positions its dataset as a source of real-time medical-benefit access insight for life sciences teams.

Buyer Fit

• Where it fits: Include SamaCare when the launch depends on medical-benefit access for provider-administered specialty drugs.
• Strong fit: Retina, oncology, neurology, rheumatology, infusion, and other buy-and-bill therapies where prior authorization and documentation friction can block starts.
• Manufacturer use case: Use SamaCare to understand real PA barriers, support clinician workflow, benchmark approval / time-to-resolution patterns, and measure interventions.
• Less natural fit: A pharmacy-benefit ePA-only program, a pure copay/PAP RFP, or a broad hub-services outsourcing decision where medical-benefit PA data is not central.
• Commercial fit: Expect custom scoping around data sharing, practice network reach, brand-program integration, privacy, intervention design, and reporting cadence.

Differentiators

• Medical-benefit depth: SamaCare focuses on the fragmented medical-benefit side of specialty medication access rather than generic pharmacy-benefit ePA.
• Provider workflow footprint: The platform is embedded in specialty-practice workflows, which can give manufacturers access signal earlier than downstream hub reporting.
• Access benchmark data: Public materials describe large prior-authorization datasets and benchmarking products for approval rates and time to resolution.
• AI-guided PA workflows: SamaCare Plus positions the platform toward touchless PA automation while keeping providers in control.
• Funding and momentum: The company raised a $17 million Series B in 2024 and publicly reported major 2025-2026 volume milestones.

RFP Questions

• Which specialties and provider networks are live for the target therapy area?
• How are manufacturer-sponsored programs, hub referrals, and provider-submitted PA data separated?
• What patient-level or aggregate data can the manufacturer receive, and under what consent / privacy model?
• How does SamaCare route cases when a hub, FRM, specialty pharmacy, or practice staff member also touches the PA?
• Which payer portals and medical-benefit workflows are automated versus manually supported?
• How does SamaCare validate AI-guided documentation recommendations before submission?
• What benchmark definitions are used for net approval rate, time to resolution, abandonment, and administrative denial?
• Which therapy-area references can show reduced delays, fewer denials, or improved start rates?

Recent Activity

• 2026: SamaCare announced more than $6.2 billion in specialty medication prior authorizations processed through its platform in 2025.
• 2026: The company launched Medical Benefit Prior Authorization Benchmarks for approval-rate and time-to-resolution visibility.
• 2025: SamaCare launched SamaCare Plus, an AI-driven touchless prior authorization offering designed to keep providers in control.
• 2025: SamaCare announced that it had resolved more than one million medical-benefit drug prior authorizations.
• 2024: SamaCare raised a $17 million Series B led by Questa Capital, with Vive Collective and South Park Commons participating.